OxyPrem AG
Zürich, Canton of Zürich, SwitzerlandSee on the mapFounded 2018
- Seed
OxyPrem AG is a Swiss medical device manufacturer developing non-invasive systems that monitor oxygenation in human tissue in real time. Its near-infrared sensors are designed to give medical teams accurate insights for clinical decisions, particularly when caring for vulnerable newborns and other high-risk patients.
- RaisedTotal raised
- $25.8M
- Aug 2019Latest priced round, Aug 2019
- Seed
- Investors
- 4
- Founded
- 2018
- Employees
- 11–50
reccy insights
OxyPrem’s latest recorded financing was an equity crowdfunding round announced on Aug 30, 2024, with $3,228,859 raised and Capital Cell identified as a lead investor. The company’s financial overview lists a valuation of 17 million EUR on that same date. Its product focus is continuous, non-invasive monitoring of tissue oxygenation in vulnerable newborns, using near-infrared light to provide clinicians with real-time information about brain oxygen levels. The NOAH Tissue Oximeter System has obtained CE marking, and the company also identifies the OxyPrem 1.4 tissue oximeter as a product. Wolf Martin and Alexander Nitsch are listed as founders. The available details point to product development and financing as the clearest documented milestones, rather than a sequence of publicly announced commercial launches or organizational changes.
Written by reccy's AI from company sites, press and funding records · updated Nov 2026
What makes OxyPrem AG distinct
- 01Provides continuous, real-time tissue oxygenation measurements using harmless, non-invasive near-infrared light.
- 02Focuses on monitoring high-risk and premature newborns.
- 03Combines reusable sensors with advanced algorithms, including self-calibration.
- 04The NOAH Tissue Oximeter System has obtained CE marking.
Technology & products2
- OxyPrem 1.4 tissue oximeter
A tissue oximeter for non-invasive monitoring of tissue oxygenation.
- NOAH Tissue Oximeter System
A CE-marked system for continuous tissue oxygenation monitoring, designed for clinical use with high-risk newborns.
- OxyPrem 1.4 tissue oximeter
- NOAH Tissue Oximeter System
- Non-invasive near-infrared tissue oxygenation sensors
- Advanced self-calibration algorithms
Research roots2
Labs and research groups this company came from or works with.
- No page yetUniversity Hospital ZurichZurich, SwitzerlandZurich, Switzerland · No page yetSpin-out
- No page yetUniversity of ZurichZurich, SwitzerlandZurich, Switzerland · No page yetSpin-out
Recent updates3
- Aug 2026Product launch
NOAH Tissue Oximeter System has obtained CE marking
extern.cloud.oxyprem.com - Nov 2025Award
Top 12: Health Techpreneur 2025
oxyprem.com - May 2025Award
Finalist at the Swissnex Internationalization Award 2025
oxyprem.com
Funding
- Equity CrowdfundingAug 2024$3.2MLed by Capital Cell
- GrantMar 2022
- GrantFeb 2020$5.5M
Investors4
- Capital Cell
About OxyPrem AG
- Products
- OxyPrem 1.4 tissue oximeter, NOAH Tissue Oximeter System
- Leadership
- Wolf MartinAlexander Nitsch
- Focus areas
- Medical devices, neonatal care, patient monitoring, tissue oximetry, near-infrared technology, diagnostics, digital health
- Headquarters
- Zürich, Canton of Zürich, Switzerland
- Founded
- 2018
- Employees
- 11–50
- Status
- Active · private